GlassScriptPhysician profile
Amanda R Hess
NPI 1902062268
$2,562.74
in general payments reported to CMS, 2019-2025
30 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $194 · 2021: $309 · 2022: $512 · 2023: $557 · 2024: $379 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.08 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $255.12 | 2019-2025 | |
| Pfizer INC. | $190.78 | 2020-2025 | |
| Astellas Pharma US INC | $184.92 | 2021-2025 | Veozah |
| Hologic Sales and Service, LLC | $174.91 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima, Novasure |
| Intuitive Surgical, INC. | $154.90 | 2023 | Da Vinci Surgical System |
| Sumitomo Pharma America, INC. | $120.16 | 2023-2024 | Myfembree |
| Mayne Pharma Commercial LLC | $113.07 | 2021-2023 | |
| Agile Therapeutics, INC. | $108.10 | 2021-2023 | Twirla |
| Shield Therapeutics INC | $72.38 | 2023-2024 | Accrufer |
| Biogen, INC. | $64.28 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $63.15 | 2020-2022 | |
| Myovant Sciences INC. | $57.84 | 2021-2022 | |
| Avion Pharmaceuticals | $55.36 | 2019-2022 | |
| Evofem Biosciences, INC. | $44.59 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.62 | 2020-2021 | |
| Organon LLC | $35.93 | 2024-2025 | Nexplanon |
| Insulet Corporation | $32.41 | 2020 | |
| Indivior INC. | $25.10 | 2024 | Sublocade |
| Smith+Nephew, INC. | $23.54 | 2024 | Pico 7, Pico 14 |
| Ardelyx, INC. | $19.11 | 2024 | Ibsrela |
| Avanos Medical | $18.77 | 2023 | On-Q* Pump and Accessories |
| Baxter Healthcare | $15.36 | 2021 | |
| Duchesnay USA Incorporated | $14.64 | 2019 | |
| Stryker Corporation | $14.30 | 2024 | Mako |
| Millicent US INC | $13.70 | 2024 | Intrarosa |
| Merck Sharp & Dohme LLC | $11.75 | 2019 | |
| Allergan, INC. | $11.67 | 2020 | |
| Minerva Surgical, INC | $11.15 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.